154 related articles for article (PubMed ID: 34295654)
1. Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse.
Guo H; Diao L; Zhou X; Chen JN; Zhou Y; Fang Q; He Y; Dziadziuszko R; Zhou C; Hirsch FR
Transl Lung Cancer Res; 2021 Jun; 10(6):2452-2474. PubMed ID: 34295654
[TBL] [Abstract][Full Text] [Related]
2. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
He Y; Zhang X; Jia K; Dziadziuszko R; Zhao S; Deng J; Wang H; Hirsch FR; Zhou C
Transl Lung Cancer Res; 2019 Aug; 8(4):352-366. PubMed ID: 31555511
[TBL] [Abstract][Full Text] [Related]
3. Galectin-9 in non-small cell lung cancer.
He Y; Jia K; Dziadziuszko R; Zhao S; Zhang X; Deng J; Wang H; Hirsch FR; Zhou C
Lung Cancer; 2019 Oct; 136():80-85. PubMed ID: 31454748
[TBL] [Abstract][Full Text] [Related]
4. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract][Full Text] [Related]
5. BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.
Li X; Xu Z; Cui G; Yu L; Zhang X
Onco Targets Ther; 2020; 13():215-224. PubMed ID: 32021268
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
Chen P; Wang H; Zhao L; Guo H; Zhang L; Zhang W; Sun C; Zhao S; Li W; Zhu J; Yu J; Wu C; He Y
Front Oncol; 2021; 11():713853. PubMed ID: 34900670
[TBL] [Abstract][Full Text] [Related]
7. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
10. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
11. Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC.
Mazzaschi G; Milanese G; Pagano P; Madeddu D; Gnetti L; Trentini F; Falco A; Frati C; Lorusso B; Lagrasta C; Minari R; Ampollini L; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Lung Cancer; 2020 Jun; 144():30-39. PubMed ID: 32361033
[TBL] [Abstract][Full Text] [Related]
12. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR
Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222
[TBL] [Abstract][Full Text] [Related]
13. Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients.
Trentini F; Mazzaschi G; Milanese G; Pavone C; Madeddu D; Gnetti L; Frati C; Lorusso B; Lagrasta CAM; Minari R; Ampollini L; Ledda RE; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Tumori; 2022 Feb; 108(1):86-92. PubMed ID: 33730957
[TBL] [Abstract][Full Text] [Related]
14. Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer.
Bocchialini G; Lagrasta C; Madeddu D; Mazzaschi G; Marturano D; Sogni F; Silini EM; Gnetti L; Becchi G; Rusca M; Carbognani P; Ventura L; Braggio C; Tiseo M; Quaini F; Ampollini L
Eur J Cardiothorac Surg; 2020 Sep; 58(3):619-628. PubMed ID: 32267920
[TBL] [Abstract][Full Text] [Related]
15. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
16. Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach.
Feng W; Li Y; Shen L; Zhang Q; Cai XW; Zhu ZF; Sun MH; Chen HQ; Fu XL
Ther Adv Med Oncol; 2021; 13():1758835920984975. PubMed ID: 33488784
[TBL] [Abstract][Full Text] [Related]
17. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
[TBL] [Abstract][Full Text] [Related]
20. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
